Agents for Dermatitis, Excluding Corticosteroids
- Name
- Agents for Dermatitis, Excluding Corticosteroids
- Accession Number
- DBCAT002323
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Pimecrolimus A topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons. Alitretinoin A vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis. Tacrolimus A calcineurin inhibitor used to prevent organ transplant rejection and to treat moderate to severe atopic dermatitis. Cromoglicic acid A medication used to treat asthma, allergic reactions of the eyes and nose, as well as other mast cell reactions. Crisaborole A non-steroidal topical medication used for the treatment of mild-moderate atopic dermatitis. Dupilumab A monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults. Tralokinumab A monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy. Abrocitinib A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. Ruxolitinib A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. Lebrikizumab An IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents. Nemolizumab Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)). Delgocitinib Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week... - Drugs & Drug Targets